SinoMab BioScience Ltd., a Hong Kong-based biopharmaceutical company, has announced the issuance of 112,810,817 new shares under a general mandate. The shares will be issued at a subscription price of HK$1.10 per share. This move is part of a subscription agreement between SinoMab and twenty-six subscribers. The initiative aims to raise capital by leveraging the general mandate, which allows the company to issue new shares up to 20% of its existing issued shares. The announcement was made by the company's Executive Director, Chairman, and CEO, Dr. Shui On Leung.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。